Dexamethasone + netilmicin

Unassigned

New Medicines

Netildex · Ocular inflammation, including post-operative, where bacterial infection or a risk of bacterial infection exists

Information

Netildex
New formulation
SIFI
SIFI

Development and Regulatory status

None
Launched
None

Jan 19: Netildex is launched in Italy, Romania, Turkey, Mexico and Lebanon, and is awaiting regulatory approval in Canada [2].

Category

A fixed dose combination of dexamethasone (cortiocosteroid) and netilmicin (aminoglycoside antibiotic)
Globally, cataracts are the leading cause of blindness, responsible for 51% of world blindness, representing 20 million people in 2010. Cataracts are a global health priority for the WHO. The prevalence increases with age. In the UK, cataracts are thought to affect around half of those aged >65 years to some degree, rising to 70% in those aged >85yrs. Surgical removal of the cataract is the only effective treatment to restore or maintain vision. Pain and inflammation are common post surgery [1].
Ocular inflammation, including post-operative, where bacterial infection or a risk of bacterial infection exists
Topical

Trial or other data

Dec 18: PIII trial to evaluate the efficacy and safety of dexamethasone/netilmicin ophthalmic gel versus dexamethasone/netilmicin eye drop solution in the prevention of post-surgery inflammation after cataract extraction by means of phaco-emulsification completes (NCT02973880; 044-SI). The randomised, multi-center, active-controlled, double-blind trial enrolled 180 patients in Italy [2].